Entera Bio Ltd. Ordinary Shares (ENTX)
Stock · NASDAQ · Health Care
$2.69as of 10/16/2026
Price chart
Active signals
ENTX Signal Track Record
How signals performed across all stocks →What ENTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -2.0% | 48% | September 23, 2026 |
| Bollinger Band Breakdown | 20 | +4.8% | 55% | September 28, 2026 |
| Bollinger Band Breakout | 20 | -5.2% | 45% | August 25, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -5.8% | 36% | July 1, 2026 |
| Any 20-session window (baseline) | -1.6% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ENTX
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacem…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 20
- Website
- enterabio.com/
Fundamentals
- 1-day range
- $2.49$2.82
- Market cap
- $139.00M
- P/E (trailing)
- —
- P/E (forward)
- -5.04
- EPS (trailing)
- $-0.35
- Dividend yield
- —
- Beta
- 1.47
- Avg. volume
- 1.87M
How Entera Bio Ltd. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
Entera Bio Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ENTXEntera Bio Ltd. Ordinary Shares$2.68▼ 3.25%Market cap $139.00MP/E —$0.91$4.2
- CRDLCardiol Therapeutics Inc. Class A Common Shares$1.1▼ 4.35%Market cap $156.77MP/E —$1.23$3.23
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ENTX Entera Bio Ltd. Ordinary Shares | $139.00M | — | $2.68 | ▼ 3.25% | $0.91$4.2 |
| CRDL Cardiol Therapeutics Inc. Class A Common Shares | $156.77M | — | $1.1 | ▼ 4.35% | $1.23$3.23 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meetingbenzinga · 10/13/2026
- These stocks are moving in today's pre-market sessionChartMill · 10/9/2026
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga · 10/9/2026
- Alignment Healthcare, RenX Enterprises And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · 10/9/2026
- Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingYahoo · 10/8/2026
- Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial ExpertiseYahoo · 10/6/2026
- Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11Benzinga · 9/25/2026
- Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight RatingBenzinga · 9/22/2026
- Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9Benzinga · 9/18/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Entera Bio gets new coverage from Guggenheim and Cantor
Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.
Entera Bio gets new coverage from Guggenheim and Cantor. Guggenheim has started coverage of Entera Bio, giving it a buy rating and a target price of $11. Cantor Fitzgerald also began coverage, assigning an overweight rating. These new ratings come as the stock trades near its 52‑week low and shows a moderate RSI of 40, indicating room for movement.